In a 2‐centre study from the UK, Kohli et al found that short‐term PCSK9 inhibitor therapy (6–12 weeks) significantly lowered plasma Lp(a) concentration by 28% in high‐risk patients, the majority of whom had heterozygous FH.19 Here, PCSK9 is linked to familial hyperaldosteronism.